Mukka Proteins Outlook Upgraded to Stable by CARE Ratings

Revenue grew 187% YoY to Rs 490 crore in Q1 FY27; outlook revised to Stable.

Reader Takeaway: Improved operational performance and equity infusion stabilize the credit outlook; watch for working capital volatility.

What just happened

CARE Ratings has reaffirmed the bank facility ratings for Mukka Proteins Ltd at CARE BBB-/A3 while upgrading the outlook from 'Negative' to 'Stable'. The rating agency cites a notable improvement in the company's operating performance during the first quarter of fiscal year 2027 as the primary driver for this revision.

Why this matters

The 'Stable' outlook indicates increased confidence from credit agencies regarding the company’s ability to manage its financial obligations. The company reported revenue of Rs 489.65 crore in Q1 FY27, bolstered by a 93% rise in average realizations and a 49% increase in sales volumes. Furthermore, an equity infusion of Rs 47 crore—via convertible warrants—is expected to strengthen the firm's capital structure and overall liquidity position.

What changes now

Management has successfully reduced consolidated inventory levels to Rs 800 crore as of August 30, 2026, down from Rs 867 crore at the end of FY26. This trend in inventory management is critical to easing the company’s working capital intensity. Additionally, the company is preparing for its new fish meal production facility in Oman, which is slated to commence operations in the second half of FY27.

Risks to watch

Despite the positive outlook, the company remains exposed to several industry-specific risks. Working capital requirements remain high due to the seasonal nature of raw material procurement. Profitability is also sensitive to price fluctuations in raw fish and fish meal, as well as foreign exchange volatility. The company must maintain adequate debt coverage ratios as it navigates these operational dependencies and the upcoming international expansion in Oman.